OrbiMed

OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
601 Lexington Avenue (at 53rd Street), 54th Floor New York, NY 10022-4629
1700 Owens Street Suite 540 San Francisco, CA 94158
Suite F 27, Grand Hyatt Plaza Santacruz (East) Mumbai, 400055, India
89 Medinat HaYehudim St Building E, 11th Floor Herzliya 4614001, Israel
Unit 4706, Raffles City Shanghai Office Tower 268 Xizang Middle Road Shanghai 200001, P.R. China
12/F International Commerce Centre 1 Austin Road West, Unit 01 Kowloon, Hong Kong

Roy Amariglio Ph.D

Principal

Mona Ashiya

Private Equity Partner

David Bonita

General Partner

Sven Borho

Partner

Evan Caplan

Principal

Sumona Chakraborty

Director

Dina Chaya

Partner, Private Equity

Nissim Darvish

Venture Partner

Michael Eggenberg

Managing Director

Lars Enstrom

Managing Director

Joshua Golomb

Partner, Public Equity

Geoffrey Hsu

General Partner

Alexandria Huynh Ph.D

Analyst

Mark R. Jelley

Partner, Credit and Royalty

Kip Kitur Ph.D

Vice President, Private Equity

Dimitri Krainc

Venture Partner

Jonathan Lee

Partner

Yifu Liu

Managing Director, Asia

Jonathan Mandelbaum

Vice President, Private Equity

St John Donnie McGrath

Venture Partner

Anat Naschitz

Venture Partner

W. Carter Neild

Managing Partner

Valerie Odegard

Venture Partner

Topher Orr

Partner, Public Equity

Trevor M. Polischuk

Public Equity Partner

Matthew S. Rizzo

General Partner

William Sawyer

Public Equity Partner

Michael B. Sheffery

Partner and Co-Founder

Natasha Shervani

Vice President

Jonathan Silverstein

Executive Partner

Vivek Sivathanu Ph.D

Vice President, Private Equity

Charles Steinman

Analyst

C. Scotland Stevens

General Partner

Clive Wang

Associate

David Wang

Partner and Senior Managing Director, Asia

Iris Wang

Partner

Steven Wang

Partner

Dimitrios Weedon

Managing Director

Matthew L. Wotiz

Principal

Stella Xing

Managing Director

Diyong Xu

Principal, Private Equity

Nate Yee

Principal

Jessica Zhang Ph.D

Senior Associate

Daniel Zhou

Managing Director, Asia

Guowei Wang Ph.D

Senior Managing Director, Asia and Partner

Past deals in Pennsylvania

Pinnacle Medicines

Series A in 2024
Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

Scout Bio

Series B in 2021
Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

Century Therapeutics

Series C in 2021
Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Harmony Biosciences

Debt Financing in 2020
Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

Passage Bio

Series B in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Passage Bio

Series A in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

TELA Bio

Private Equity Round in 2017
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.